FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials
This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, is announcing today that the U.S. Food and Drug Administration's (FDA's) Center for Drug Evaluation...
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. Real World Evidence (RWE) patient data collected in the study confirms Orthocell's nerve repair product, Remplir, as the ideal medical device for connecting severed nerves,...
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens Servier's neurology pipeline in line with its 2030 strategy SURESNES, France,...
Gushengtang’s H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net profit significantly outpaced top-line growth, reflecting improved profitability and...
Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges
BANGKOK, Sept. 8, 2025 /PRNewswire/ -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place from October 31 to November 2, 2025. Applications are now open for participants across Southeast Asia. The event aims to bring together multidisciplinary professionals...
Merz Aesthetics® Tops Best Workplaces in Asia™ 2025 List by Great Place To Work®
SINGAPORE, Sept. 8, 2025 /PRNewswire/ -- Merz Aesthetics, the world's largest dedicated medical aesthetics business has officially been recognized as No.1 under Best Workplace in Asia 2025 in the Small & Medium Business category by Great Place To Work, celebrating its commitment to a truly inclusive, people-first culture. Team Merz Aesthetics Asia-Pacific...
Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines
HONG KONG, Sept. 7, 2025 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms...
Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry. This...
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) outcomes In the HARMONi trial, clinical endpoint benefits, including OS and PFS, were consistent...
New Board, New Strategy: Home Control Taps Global Perspectives to Drive Smart Healthcare Expansion
HONG KONG, Sept. 6, 2025 /PRNewswire/ -- Traditionally in Hong Kong's capital market, Home Control (1747.HK) has often been described as a "hidden gem". The company has maintained a solid financial track record with consistent dividend payouts, yet has rarely been in the market spotlight. Recently, the appointment of several new directors has drawn significant investor attention, propelling the...
